Guggenheim raises PT on ANI Pharma after Alimera deal completion

ANI Pharmaceuticals

17/09/2024 12:28

** Brokerage Guggenheim raises PT on ANI Pharmaceuticals 
 ANIP.O  to $83 from $77, retains "buy" rating
    ** New PT represents a 47.7% upside to stock's last close  
    ** Says, updating its model following the close of the
Alimera acquisition 
     ** On Monday, ANIP announced it completed its acquisition
of Alimera Sciences  ALIM.O , expanding its rare disease
business
    ** Brokerage estimates FY24 product revenues of $34.4 mln
for Alimera, including sales of $4.1 mln for the last ~2 weeks
of Q3 2024, which will be recorded by ANIP
    ** Says deal to have positive impact on ANIP's outlook
    ** Average rating of 5 brokerages is equivalent to "buy";
median PT is $83
    ** Up to last close, stock up 1.9% YTD  

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))